Wednesday, October 25, 2017 9:19:06 AM
MacroGenics skyrockets after Incyte deal
MacroGenics ($MGNX) skyrockets in premarket trading after the company inks a licensing deal with Incyte ($INCY) covering its MGA012 antibody.
Under the terms of the arrangement, Incyte pays MacroGenics an upfront payment of $150M and lands global development rights for MGA012.
Shares of MGNX are up 35% premarket to $21.80.
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM